NCCN VERSION 2 2015

183 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-108
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
2005;105:642-643. Available at:
.
564. Witzel ID, Müller V, Harps E, et al. Trastuzumab in pregnancy
associated with poor fetal outcome. Ann Oncol 2008;19:191-192.
Available at: .
565. Kelly H, Graham M, Humes E, et al. Delivery of a healthy baby
after first-trimester maternal exposure to lapatinib. Clin Breast Cancer
2006;7:339-341. Available at:
.
566. Dawood, S, Cristofanilli M. What progress have we made in
managing inflammatory breast cancer? Oncology 2007;21:673-679.
Available at:
567. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast
cancer: a review. J Clin Oncol 1992;10:1014-1024. Available at:
568. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling
identifies molecular subtypes of inflammatory breast cancer. Cancer
Res 2005;65:2170-2178. Available at:
.
569. Van Laere SJ, Van den Eynden GG, Van der Auwera I, et al.
Identification of cell-of-origin breast tumor subtypes in inflammatory
breast cancer by gene expression profiling. Breast Cancer Res Treat
2006;95:243-255. Available at:
.
570. Zell JA, Tsang WY, Taylor TH, et al. Prognostic impact of human
epidermal growth factor-like receptor 2 and hormone receptor status in
inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases
from the California Cancer Registry. Breast Cancer Res 2009;11:R9.
Available at: .
571. Parton M, Dowsett M, Ashley S, et al. High incidence of HER-2
positivity in inflammatory breast cancer. Breast 2004;13:97-103.
Available at: .
572. Haagensen CD. Inflammatory Carcinoma. Diseases of the Breast.
Philadelphia: WB Saunders; 1956:488-498.
573. Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast
cancer (IBC) and patterns of recurrence: understanding the biology of a
unique disease. Cancer 2007;110:1436-1444. Available at:
.
574. Panades M, Olivotto IA, Speers CH, et al. Evolving treatment
strategies for inflammatory breast cancer: a population-based survival
analysis. J Clin Oncol 2005;23:1941-1950. Available at:
.
575. Dawood S, Ueno NT, Valero V, et al. Differences in survival among
women with stage III inflammatory and noninflammatory locally
advanced breast cancer appear early: a large population-based study.
Cancer 2011;117:1819-1826. Available at:
.
576. Hance KW, Anderson WF, Devesa SS, et al. Trends in
inflammatory breast carcinoma incidence and survival: the surveillance,
epidemiology, and end results program at the National Cancer Institute.
J Natl Cancer Inst 2005;97:966-975. Available at:
.
577. Li J, Gonzalez-Angulo AM, Allen PK, et al. Triple-negative subtype
predicts poor overall survival and high locoregional relapse in
inflammatory breast cancer. Oncologist 2011;16:1675-1683. Available
at:
578. Dawood S, Broglio K, Gong Y, et al. Prognostic significance of
HER-2 status in women with inflammatory breast cancer. Cancer
2008;112:1905-1911. Available at:
.